Association of MiR-155 Expression with Prognosis in Resected Stage III Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2014.05.10
- VernacularTitle:pIII期非小细胞肺癌中miR-155的表达与预后关系的研究
- Author:
GAO YI
1
;
FU SHENGLING
;
JIANG WENYANG
;
LI BINFENG
;
TIAN YITAO
;
FU XIANGNING
Author Information
1. 华中科技大学同济医院胸外科
- Keywords:
Lung neoplasms;
MiR-155;
Prognosis
- From:
Chinese Journal of Lung Cancer
2014;(5):417-423
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Despite undergoing curative resection, the 5-year survival rate for stage III non-small cell lung cancer (NSCLC) patients is less than 25%. hTere is a need for biomarkers for prediction of survival and guiding individual therapy. MiR-155 is one of most commonly upregulated miRNAs in malignancies, and regulates multiple pro-oncogenic pathways. We aimed to investigate the prognostic impact of miR-155 in resected stage III NSCLC patients. Methods Tumor formalin-ifxed, paraffn-embedded (FFPE) from 162 resected stage III NSCLC patients were collected. Total RNA including miRNA was extracted, and qRT-PCR was used to determine the expression of miR-155. Results Spearman rank correlation test showed a positive correlation between miR-155 expression and nodal status (r=0.169, P=0.032). MiR-155 expression had a signiifcant prognostic impact in the total cohort (P<0.001), in squamous cell carcinomas (P=0.002) and in adenocarcinomas (P=0.003). In N0-1 subgroup, miR-155 expression did not have a signiifcant prognostic on overall survival in univariate analysis (P=0.319). In N2 subgroup, miR-155 had a negative prognostic effect on OS in univariate analysis (P<0.001). Cox regression analysis revealed that miR-155 expression was unfavorable prognostic factors of OS (RR=2.311, 95%CI:1.479-3.611, P<0.001). Conclusion High expression of miR-155 represents a valuable marker of poor clinical outcomes in patients with stage III NSCLC.
